This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 202| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2329 | IMMT | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.3) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2330 | DDX1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.16) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2331 | NUDC | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2332 | HT010 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2333 | RAN | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2334 | PDHB | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.13) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2335 | SCA1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.12) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2336 | PTENP1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.11) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2337 | HFL3 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 2.0) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2338 | PMS2L11 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.83) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2339 | SGK | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.64) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2340 | GPRK6 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.59) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2341 | ZNF216 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.54) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2342 | TIAL1 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.53) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2343 | KIAA0564 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.48) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2344 | GADD45B | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.41) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2345 | TAPBP | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.35) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2346 | RHO6 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.25) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2347 | SLC9A3R2 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.23) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2348 | HFL1 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.23) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2349 | CG018 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.23) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2350 | PIK3R1 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.22) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2351 | CYP3A5P2 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.21) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2352 | LAMP2 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.20) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2353 | AQP3 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.19) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2354 | SEMA6C | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.19) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2355 | SAT | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.18) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2356 | PTPRD | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.15) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2357 | MASP2 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.15) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2358 | GADD45B | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
| 2359 | RhoC | Protein and RNA | Human | Upregulated in highly invasive NHCC than in less invasive SLHCC and upregulated in EHML (Extrahepatic Metastatic Lesions) than HCC and PCLT (Pericarcinomatous liver tissues). | Prognostic | EHML (Extrahepatic Metastatic Lesions) v/s HCC and PCLT(pericarcinomatous liver tissues); increased RhoC expression strongly correlates with vein invasion | p < 0.01 | Tissue | 15150600 |
| 2360 | PARD3, INSIG1, MPHOSPH9, SKP2, CUL4B, CETN2, ETS2, USH1C, PTPN11, OASL, ARL5, SMURF2, CDC42SE1, CSNK1G3, RACGAP1, DNAJC10, KCNK1, CDO1, CNGA1, NUDT9, GSTM3, SLC16A5, SARA2, ID2, MTHFD2L, SYNGR2, PRL10A, RNF130, MAFB, FLJ23749, LARP6, R3HDM, ZNF652, PGGT1B, HEXB, SLC27A2, ZBTB38, SH3GLB2, AGPAT3, GCH | RNAs | Human | Differentially expressed between recurrence HCC disease | Prognostic | Recurrent v/s non-recurrent HCC | p < 0.05 | Tissue | 17975138 |
| 2433 | AURKB | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.36 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2434 | AZI1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.46 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2435 | LOC654342 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.58 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2436 | TPR | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.86 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2437 | CENPI | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.69 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2438 | CBX1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.68 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2439 | CCHCR1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.57 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2440 | STMN1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.52 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2441 | AUP1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.33 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2442 | IQGAP3 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.24 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2443 | NFYA | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.41 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2444 | TH1L | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.54 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2445 | SLC39A4 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 4.42 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2446 | MEIS2 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.28 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2447 | CIT | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.26 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2448 | KIAA0286 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.99 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2449 | FAM48A | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.83 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2450 | CCNF | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.72) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |